Login to Your Account

Other News To Note

Wednesday, August 28, 2013
• Athera Biotechnologies AB, of Stockholm, a Karolinska Development AB portfolio company, said it transferred rights to the recombinant Annexin A5 product to Medirista AB, also of Stockholm. Financial terms were not disclosed.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription